MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317955 | Name: Fosinopril Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fosinopril Sodium is a phosphinic acid-containing ACE (angiotensin-converting enzyme) inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.

Chemical Structure

Fosinopril Sodium
Fosinopril Sodium
CAS#88889-14-9 (sodium)

Theoretical Analysis

MedKoo Cat#: 317955

Name: Fosinopril Sodium

CAS#: 88889-14-9 (sodium)

Chemical Formula: C30H45NNaO7P

Exact Mass: 0.0000

Molecular Weight: 585.64

Elemental Analysis: C, 61.53; H, 7.74; N, 2.39; Na, 3.93; O, 19.12; P, 5.29

Price and Availability

Size Price Availability Quantity
250mg USD 250.00 2 Weeks
500mg USD 400.00 2 Weeks
1g USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
98048-97-6 (free acid) 88889-14-9 (sodium)
Synonym
Fosinopril Sodium; Monopril; Staril; Dynacil; Fosinil; Tenso Stop; Tensocardil; Sodium, Fosinopril; SQ 28,555; SQ 28555; SQ-28,555; SQ-28555; SQ28,555; SQ28555; Squibb Brand of Fosinopril Sodium; Staril;
IUPAC/Chemical Name
sodium (2S,4S)-4-cyclohexyl-1-(2-(((S)-2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
InChi Key
TVTJZMHAIQQZTL-TXDYNIFHSA-M
InChi Code
InChI=1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1
SMILES Code
O=C([C@H]1N(C[C@@H](C1)C2CCCCC2)C(CP(CCCCC3=CC=CC=C3)(O[C@H](OC(CC)=O)C(C)C)=O)=O)[O-].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 585.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang DW, Zhang L, Liu JG, Wang CL, Shi DZ, Chen KJ. [Protective effect of fosinopril sodium pretreatment combined with ischemic postconditioning on rat heart underwent myocardial ischemia/reperfusion injury]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Jul;38(7):633-7. Chinese. PubMed PMID: 21055289. 2: Jancić B, Medenica M, Ivanović D, Janković S, Malenović A. Monitoring of fosinopril sodium impurities by liquid chromatography-mass spectrometry including the neural networks in method evaluation. J Chromatogr A. 2008 May 2;1189(1-2):366-73. Epub 2007 Dec 4. PubMed PMID: 18154978. 3: Janci B, Medenica M, Ivanović D, Malenović A, Marković S. Microemulsion liquid chromatographic method for characterisation of fosinopril sodium and fosinoprilat separation with chemometrical support. Anal Bioanal Chem. 2005 Oct;383(4):687-94. Epub 2005 Sep 30. PubMed PMID: 16195875. 4: Mousa D, Rassoul Z, Popovich W, Hassan A, Margate V, Hawas F, Suleiman M, Al Khader A. A new treatment forInterdialytic hyperkalemia - the use of fosinopril sodium. Am J Nephrol. 1999;19(3):395-9. PubMed PMID: 10393377. 5: Migdalis IN, Gerolimou B, Kozanidou G, Hatzigakis SM, Karmaniolas KD. Effect of fosinopril sodium on early carotid atherosclerosis in diabetic patients with hypertension. J Med. 1997;28(5-6):371-80. PubMed PMID: 9604795. 6: Lewen N, Schenkenberger M, Larkin T, Conder S, Brittain HG. The determination of palladium in fosinopril sodium (monopril) by ICP-MS. J Pharm Biomed Anal. 1995 Jun;13(7):879-83. PubMed PMID: 8562611. 7: Wang Z, Morris KR, Chu B. Aggregation behavior of fosinopril sodium--a new angiotensin-converting enzyme inhibitor. J Pharm Sci. 1995 May;84(5):609-13. PubMed PMID: 7658352. 8: Lozano R, Warren FV Jr, Perlman S, Joseph JM. Quantitative analysis of fosinopril sodium by capillary zone electrophoresis and liquid chromatography. J Pharm Biomed Anal. 1995 Feb;13(2):139-48. PubMed PMID: 7766720. 9: Friberg SE, Moaddel T, Morris KR, Abramowitz R, Amsberry KL. A lamellar liquid crystal with fosinopril sodium. J Pharm Sci. 1994 May;83(5):677-9. PubMed PMID: 8071820. 10: Desmet W, Vrolix M, De Scheerder I, Van Lierde J, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation. 1994 Jan;89(1):385-92. PubMed PMID: 8281674. 11: Brittain HG, Morris KR, Bugay DE, Thakur AB, Serajuddin AT. Solid-state NMR and IR for the analysis of pharmaceutical solids: polymorphs of fosinopril sodium. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1063-9. PubMed PMID: 8123714. 12: Thakur AB, Morris K, Grosso JA, Himes K, Thottathil JK, Jerzewski RL, Wadke DA, Carstensen JT. Mechanism and kinetics of metal ion-mediated degradation of fosinopril sodium. Pharm Res. 1993 Jun;10(6):800-9. PubMed PMID: 8391696. 13: Duchin KL, Waclawski AP, Tu JI, Manning J, Frantz M, Willard DA. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. J Clin Pharmacol. 1991 Jan;31(1):58-64. PubMed PMID: 1646240. 14: Waldemar G, Ibsen H, Strandgaard S, Andersen AR, Rasmussen S, Paulson OB. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. Am J Hypertens. 1990 Jun;3(6 Pt 1):464-70. PubMed PMID: 2142429. 15: Morrison RA, Singhvi SM, Peterson AE, Pocetti DA, Migdalof BH. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies. Drug Metab Dispos. 1990 Mar-Apr;18(2):253-7. PubMed PMID: 1971582. 16: Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 1988 Jan;25(1):9-15. PubMed PMID: 2967089; PubMed Central PMCID: PMC1386608.